1 / 29

American Heart Association Scientific Sessions

American Heart Association Scientific Sessions. Importance of Targeting LDL-C. Trial Designs Compared Statins. Are Statins Enough?. Residual Risk Poorly Managed. PCSK9 Inhibitors. How Low is Too Low?. Please join us as we move on to the next interview. PCSK9 Inhibitors Clinical Trials.

rudyard-wyatt
Download Presentation

American Heart Association Scientific Sessions

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. American Heart Association Scientific Sessions

  2. Importance of Targeting LDL-C

  3. Trial Designs Compared Statins

  4. Are Statins Enough?

  5. Residual Risk Poorly Managed

  6. PCSK9 Inhibitors

  7. How Low is Too Low?

  8. Please join us as we move on to the next interview.

  9. PCSK9 Inhibitors Clinical Trials

  10. Practicalities of PCSK9 Inhibitors

  11. Few Clinical Barriers

  12. PCSK9 Inhibitors Their Place in the Armamentarium

  13. 2013 ACC/AHA Guidelines

  14. Role of PCSK9 Inhibitor in Future Recommendation

  15. Future Drug Therapy

  16. Closing Thoughts

  17. Abbreviations

  18. References

  19. References (cont)

  20. References (cont)

More Related